Natera and Angiex Partner to Assess Response to Investigational Nuclear-Delivered Antibody-Drug Conjugate™ Using Signatera™
Natera partnered with Angiex to deploy its Signatera test in a Phase I trial of AGX101, a novel Nuclear-Delivered Antibody-Drug Conjugate for advanced solid tumors. The collaboration will use longitudinal circulating tumor DNA monitoring to assess treatment response, aiming to complement radiologic assessments for patients with unresectable or metastatic disease.
Key figures
- Drug Name
- AGX101
- Phase Of Trial
- Phase I
- Target antigen
- TM4SF1
- Clinical trial id
- NCT06440005
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.